EC
SNDX icon

EntryPoint Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

EntryPoint Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,090
Closed -$22.4K – 1094
2024
Q2 		$22.4K Sell
1,090
-7,546
-87% -$158K 0.03% 699
2024
Q1 		$206K Buy
8,636
+7,165
+487% +$160K 0.18% 110
2023
Q4 		$31.8K Buy
+1,471
New +$22.6K 0.03% 903

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EntryPoint Capital's SNDX Position: Q3 2024 in Review

EntryPoint Capital sold out of Syndax Pharmaceuticals (SNDX) in Q3 2024, closing a stake of 1,090 shares — an estimated $22.4K sold.

EntryPoint Capital first reported a position in SNDX in Q4 2023 and held it in 3 quarters. The position peaked at $206K in Q1 2024. 210 funds tracked by Wall St. Rank hold SNDX as of Q3 2024.

  • EntryPoint Capital reported no remaining Syndax Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 1,090 Syndax Pharmaceuticals shares in Q3 2024, an estimated $22.4K.
  • EntryPoint Capital first reported a position in Syndax Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • EntryPoint Capital's Syndax Pharmaceuticals position peaked at $206K in Q1 2024.
  • 210 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.